NSAIDs, including ZIPSOR, can cause serious skin adverse events such as exfoliative dermatitis,
Stevens-Johnson Syndrome, and toxic epidermal necrolysis, which can be fatal. These serious events can occur without warning. Continue reading below...
Patient will take their ZIPSOR prescription and Savings
Card to their pharmacist
Commercially insured patients can automatically
receive prescription savings applied at more than
41,000 participating pharmacies†
Non-Interchangeability With Other Formulations of Diclofenac
Different formulations of oral diclofenac are not bioequivalent even if the milligram strength is the same. Therefore, it is not
possible to convert dosing from any other formulation of diclofenac to ZIPSOR.
*Restrictions apply. See terms and conditions for further details.
†Participation status subject to change.
Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.
Terms and Conditions
A valid prescription for ZIPSOR must be presented.
Offers not valid for prescriptions covered by or reimbursed under Medicaid, a Medicare drug benefit program or other federal or state programs (such as medical
assistance programs). If Patient is eligible for drug benefits under any such program, they cannot receive this copay assistance. By participating in either copay
assistance program, the Patient agrees they will not submit a claim for their prescription to a government payor.
Cannot be combined with any other programs, discounts, coupons, certificates, vouchers, or similar offers. Void where taxed, restricted, or prohibited by law. Product
dispensed pursuant to program rules, and federal and state laws. The parties reserve the right to rescind, revoke, or amend the programs at any time without notice.
Offers not extended to clubs, groups, or organizations. Participation in this program must comply with all applicable state laws and contractual or other obligations as a
pharmacy provider. These are not insurance programs. Participating patients and pharmacists understand and agree to comply with the terms and conditions as set
forth herein.
This offer is good only in the United States at participating retail pharmacies and cannot be redeemed at government-subsidized clinics. eVoucherRx™ offer not
extended on prescriptions for patients that are cash-paying customers, using mail-order or institution-based pharmacies to fill their prescriptions, filling their
prescriptions at a nonparticipating pharmacy, or federal or state government employees.
Offer applies to out-of-pocket expenses of more than $0 for ZIPSOR. Out-of-pocket copay expenses greater than $0 will be covered up to a $100 benefit per qualified
prescription and/or up to 2 refill prescription copay benefits per commercially insured Patient.
This offer is good only in the United States at participating retail pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or
prohibited by law.
eVoucherRx™ program is sponsored by RelayHealth.
ZIPSOR® (diclofenac potassium) Liquid Filled Capsules are indicated for relief of mild to moderate acute pain in adults (18 years of age or older).
Carefully consider the potential benefits and risks of ZIPSOR and other treatment options before deciding to use ZIPSOR. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
Different dose strengths and formulations of oral diclofenac are not interchangeable. This difference should be taken into consideration when changing strengths or formulations. The only approved dosing regimen for ZIPSOR is 25 mg four times a day.
ZIPSOR is contraindicated in the following patients:
Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal.
To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Post-MI Patients
Avoid the use of ZIPSOR in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ZIPSOR is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.
NSAIDs, including diclofenac, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic.
Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue ZIPSOR immediately, and perform a clinical evaluation of the patient. Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics).
To minimize the potential risk for an adverse liver-related event in patients treated with ZIPSOR, use the lowest effective dose for the shortest duration possible.
NSAIDs, including ZIPSOR, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs.
Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.
A meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.
Avoid the use of ZIPSOR in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ZIPSOR is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Renal Toxicity
Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ZIPSOR in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
Diclofenac has been associated with anaphylactic reactions in patients with and without known hypersensitivity to diclofenac and in patients with aspirin-sensitive asthma.
ZIPSOR is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
NSAIDs, including diclofenac, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome, and toxic epidermal necrolysis, which can be fatal. These serious events can occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of ZIPSOR at the first appearance of skin rash or any other sign of hypersensitivity. ZIPSOR is contraindicated in patients with previous serious skin reactions to NSAIDs.
Anemia has occurred in NSAID-treated patients. If a patient treated with ZIPSOR has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.
NSAIDs, including ZIPSOR, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding.
The most common adverse reactions reported in ZIPSOR clinical trials (≥1% and greater than placebo) were abdominal pain, constipation, somnolence, and increased sweating.
Monitor patients for bleeding who are concomitantly taking ZIPSOR with drugs that interfere with hemostasis. Concomitant use of ZIPSOR and analgesic doses of aspirin is not generally recommended.
Concomitant use with ZIPSOR may diminish the antihypertensive effect of these drugs. Monitor blood pressure.
Concomitant use with ZIPSOR in elderly volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function.
NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects.
Concomitant use with ZIPSOR can increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels.
Please see full Prescribing Information for complete information about Drug Interactions.
Pregnancy Category C prior to 30 weeks gestation; Category D starting 30 weeks gestation.
Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation.
NSAIDs are associated with reversible infertility. Consider withdrawal of ZIPSOR in women who have difficulties conceiving.
Risk Summary
It is not known whether this drug is excreted in human milk; however, there is a case report in the literature indicating that diclofenac can be detected at low levels in breast milk.
Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ZIPSOR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of ZIPSOR in pediatric patients has not been established.
Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects.
Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare.
References: 1. Riff DS, Duckor S, Gottlieb I, et al. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther. 2009;31(10):2072-2085. 2. Daniels SE, Baum DR, Clark F, Golf MH, McDonnell ME, Boesing SE. Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain. Curr Med Res Opin. 2010;26(10):2375-2384. 3. ZIPSOR [package insert]. Newark, CA: Depomed, Inc.; 2012.
Reference: 1. ZIPSOR [package insert]. Newark, CA: Depomed, Inc.; 2012.
References: 1. ZIPSOR [package insert]. Newark, CA: Depomed, Inc.; 2012. 2. Lissy M, Scallion R, Stiff DD, Moore K. Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. Expert Opin Pharmacother. 2010;11(5):701-708.
ProSorb is a registered trademark of Depomed, Inc.
Reference: 1. Symphony Health Solutions, Dynamic Claims, January 2012-December 2012. Approved percentage calculated using approved plus reversed claims.